Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; appointments solution for online appointments, reminders, and referral tracking; and patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and PRO data for approximately 25 specialties; and life sciences solution to deliver targeted and clinically relevant marketing content to patients, as well as COVID-19 product offerings for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was founded in 2005 and is headquartered in Raleigh, North Carolina.
IPO Year: 2019
Exchange: NYSE
Website: phreesia.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2024 | $35.00 | Buy | Truist |
| 1/17/2024 | $30.00 → $32.00 | Neutral → Buy | DA Davidson |
| 1/3/2024 | $29.00 | Overweight | Barclays |
| 4/12/2023 | $37.00 | Overweight | Stephens |
| 1/4/2023 | $35.00 → $40.00 | Buy | Needham |
| 12/13/2022 | $40.00 | Neutral → Buy | Citigroup |
| 12/9/2022 | $31.00 → $34.00 | Mkt Perform → Outperform | SVB Leerink |
| 10/13/2022 | $25.00 | Neutral | DA Davidson |
| 9/16/2022 | $40.00 | Overweight | KeyBanc Capital Markets |
| 4/14/2022 | $45.00 | Buy | Guggenheim |
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2025 financial results after the close of market trading on Monday, Dec. 9, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit th
Phreesia, a leader in patient intake, outreach and activation, and a member of Oracle PartnerNetwork (OPN), today announced that it has achieved Oracle Validated Integration with Oracle Health Electronic Health Record (EHR) Expertise for its integration of the Phreesia platform. Phreesia gives clients a suite of tools to manage patient intake across care settings and service lines. Its logic-driven tools enable healthcare organizations to operate more efficiently and provide a high-quality patient experience at scale. Expertise is a core tenet of the Oracle PartnerNetwork (OPN) program and allows Oracle partners to highlight their capabilities in a focused area. Ultimately, Expertise is de
Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati
Messaging at the point of care encourages patients to take steps toward improving their mental health Phreesia, a leader in patient intake, outreach and activation, has collaborated with the Ad Council, a nonprofit organization at the forefront of driving change through social impact marketing, to bring three public health campaigns about mental health directly to patients and caregivers. Collectively across the campaigns, Phreesia has already delivered more than 430,000 messages, helping to spread awareness about the importance of youth and adult mental wellbeing and encouraging more open conversations about mental health. Key Phreesia findings among patients and caregivers who consented
Phreesia, a leader in patient intake, outreach and activation, is pleased to announce that its contract with the CMS Innovation Center (CMMI) for use of the Patient Activation Measure® (PAM) has been renewed through 2029. The PAM performance measure, which assesses gains in patients' knowledge, skills and confidence in managing their own healthcare, is one of the first patient-reported outcome performance measures (PRO-PMs) used in a CMS alternative payment model. Under the new contract, Phreesia will provide access to PAM, training, analysis and other support to the Kidney Care Choices Model (KCC). CMMI also has the option to expand the PAM into additional models, including those focused o
Findings reveal that delivering digital, vaccine-related messages before medical appointments more than doubles the rate of vaccine uptake. New Phreesia research examining more than 20.2 million digital vaccine messages indicates that providing adults and caregivers with vaccine information just before their appointments, or at the point of care, is an effective strategy for supporting vaccine confidence and adoption, including among historically marginalized populations. Between March 2020 and May 2024, Phreesia delivered vaccine messages to patients in all 50 states, just before appointments in various care settings. Patients were segmented into subpopulations based on demographics, vac
Phreesia, a leader in patient intake, outreach and activation, together with the National Association For Continence (NAFC), Health.Equity.Outcomes. and Christina Escobar, MD, at New York University, are proud to announce that the U.S. Centers for Disease Control and Prevention (CDC) has awarded a research grant for a joint project focused on combating the public health challenge of urinary incontinence (UI) in women. This grant will fund a campaign to raise awareness of UI, which affects nearly 100 million women in the U.S. but remains underdiagnosed, undertreated and underdiscussed. Deployed on Phreesia's digital patient engagement platform, the campaign will aim to empower women to star
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2024. "We reached another very important milestone in Phreesia's evolution by crossing over to positive Free cash flow1 in the fiscal second quarter of 2025," said CEO and Co-Founder Chaim Indig. "We believe this milestone marks the start of a new era for Phreesia in which we are able to deploy internally generated cash to drive stakeholder value." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2025 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2024 Highlights Total revenue was
Collaboration aims to boost vaccination as coverage rates remain below pre-pandemic levels Phreesia, a leader in patient intake, outreach and activation, and the American Academy of Pediatrics (AAP), an organization of 67,000 pediatricians, have joined forces to increase measles, mumps and rubella (MMR) immunization by reaching parents and caregivers of eligible or soon-to-be eligible children at the point of care. The collaboration comes as immunization rates have dipped in some communities, pointing to a need to improve access to the vaccines that can help keep children healthy. Through a joint campaign that will run on Phreesia's digital intake platform, the organizations will engage
Phreesia Welcomes Former CEO of ENT and Allergy Associates Phreesia, a leader in patient intake, outreach and activation, is pleased to announce it has named Bob Glazer as a Strategic Advisor, leveraging his deep expertise and decades of experience in healthcare leadership to help ensure its offerings continue to meet the evolving needs of its clients. Glazer, whose career spans more than 45 years, is currently the President of Glazer Business Advisors, a consulting group that advises physician practices in areas such as physician recruitment, revenue cycle management, mergers and acquisitions, and strategic planning. Glazer spent 27 years as CEO of ENT and Allergy Associates (ENTA), th
10-Q - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
10-Q - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
ARS - Phreesia, Inc. (0001412408) (Filer)
DEFA14A - Phreesia, Inc. (0001412408) (Filer)
DEF 14A - Phreesia, Inc. (0001412408) (Filer)
S-8 - Phreesia, Inc. (0001412408) (Filer)
Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati
Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Audrey Gato, Vice President of Client Solutions, has been named to The Software Report's list of the Top 50 Women Leaders in SaaS of 2023. Honorees were chosen based on their leadership and contributions to the Software-as-a-Service industry. This is the sixth consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; Kharen Hauck, Vice President of Marketing; Amy VanDuyn, Senior Vice President of Human Resources; and Sara DiNardo, Vice President of Client Solutio
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2025 financial results after the close of market trading on Monday, Dec. 9, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit th
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2024. "We reached another very important milestone in Phreesia's evolution by crossing over to positive Free cash flow1 in the fiscal second quarter of 2025," said CEO and Co-Founder Chaim Indig. "We believe this milestone marks the start of a new era for Phreesia in which we are able to deploy internally generated cash to drive stakeholder value." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2025 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2024 Highlights Total revenue was
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal second quarter 2025 financial results after the close of market trading on Wednesday, Sept. 4, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal second quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or v
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2024. "I am tremendously proud of our team's commitment to our growth and profitability1 objectives." said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal Year 2025 Stakeholder Letter. Fiscal First Quarter Ended April 30, 2024 Highlights Total revenue was $101.2 million in the quarter, up 21% year-over-year. Average number of healthcare services clients ("AHSCs") was 4,065 in the quarter, up 23% year-over-year. Healthcare services revenue per AHSC was $18
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal first quarter 2025 financial results after the close of market trading on Thursday, May 30, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal first quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or visit
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2024. "Phreesia ended fiscal year 2024 with strong momentum going into fiscal 2025. We facilitated more than 150 million patient visits in fiscal 2024, or more than one in ten patient visits across the U.S. We are confident that our solutions and our team position us for continued growth and a return to profitability1," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal Year 2024 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2024 H
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal fourth quarter 2024 financial results after the close of market trading on Thursday, March 14, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal fourth quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or v
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2023. "I am proud of our work during the third quarter to further our mission of helping patients take a more active role in their care," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q3 Fiscal Year 2024 Stakeholder Letter. Fiscal Third Quarter Ended October 31, 2023 Highlights Total revenue was $91.6 million in the quarter as compared to $73.1 million in the same period in the prior year, an increase of 25%. Average number of healthcare services clients ("AHSC
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2024 financial results after the close of market trading on Tuesday, December 5, 2023. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or vi
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2023. "I am incredibly pleased and proud of our team's accomplishments in the second quarter of fiscal year 2024. We continued to deliver excellent value for our clients and scale our business—all while helping patients take a more active role in their healthcare and achieve improved health outcomes," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2024 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2023 Highlights Total revenue was $85.8 mill
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley cut the price target for Microchip Technology Incorporated (NASDAQ:MCHP) from $102 to $100. Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. Microchip Technology shares rose 3.9% to close at $95.98 on Wednesday. See how other analysts view this stock. Truist Securities lifted the price target for Astrana Health, Inc. (NASDAQ:ASTH) from $44 to $50. Truist Securities analyst Jailendra Singh upgraded the stock from Hold to Buy. Astrana Health sha
Keybanc analyst Scott Schoenhaus maintains Phreesia (NYSE:PHR) with a Overweight and lowers the price target from $27 to $25.
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:PHR) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.83, a high estimate of $34.00, and a low estimate of $28.00. A decline of 4.79% from the prior average price ta
Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:PHR) with a Buy and maintains $29 price target.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PHR PUT TRADE NEUTRAL 06/21/24 $20.00 $570.0K 3.2K 3.1K LLY CALL SWEEP BEARISH 06/07/24 $850.00 $87.7
Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:PHR) with a Buy and lowers the price target from $35 to $29.
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
Canaccord Genuity analyst Richard Close maintains Phreesia (NYSE:PHR) with a Buy and lowers the price target from $37 to $34.
Stephens & Co. analyst Jeff Garro reiterates Phreesia (NYSE:PHR) with a Overweight and maintains $28 price target.
JMP Securities analyst Joe Goodwin reiterates Phreesia (NYSE:PHR) with a Market Outperform and maintains $30 price target.
Truist initiated coverage of Phreesia with a rating of Buy and set a new price target of $35.00
DA Davidson upgraded Phreesia from Neutral to Buy and set a new price target of $32.00 from $30.00 previously
Barclays initiated coverage of Phreesia with a rating of Overweight and set a new price target of $29.00
Stephens initiated coverage of Phreesia with a rating of Overweight and set a new price target of $37.00
Needham reiterated coverage of Phreesia with a rating of Buy and set a new price target of $40.00 from $35.00 previously
Citigroup upgraded Phreesia from Neutral to Buy and set a new price target of $40.00
SVB Leerink upgraded Phreesia from Mkt Perform to Outperform and set a new price target of $34.00 from $31.00 previously
DA Davidson initiated coverage of Phreesia with a rating of Neutral and set a new price target of $25.00
KeyBanc Capital Markets initiated coverage of Phreesia with a rating of Overweight and set a new price target of $40.00
Guggenheim initiated coverage of Phreesia with a rating of Buy and set a new price target of $45.00